ArticleIJU case reports2026
Cavitation of Pulmonary Metastases During Enfortumab Vedotin for Metastatic Ureteral Urothelial Carcinoma.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cavitation of Pulmonary Metastases During Enfortumab Vedotin for Metastatic Ureteral Urothelial Carcinoma.IJU case reports · 2026Article
- Neoadjuvant Avelumab Plus Axitinib Enabling Curative Resection of Renal Cell Carcinoma With Direct Liver Invasion: A Case Report.IJU case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Enfortumab vedotin (EV), a Nectin-4-targeted antibody-drug conjugate, is active in previously treated urothelial carcinoma. Cavitation of pulmonary metastases is classically linked to squamous histology or anti-angiogenic/cytotoxic regimens; rarely reported under EV. Case Presentation: A 69-year-old woman with upper-tract urothelial carcinoma developed pulmonary and hepatic metastases. During EV, multiple lung nodules rapidly cavitated into thin-walled lesions while liver disease shrank. No infectious symptoms; overall survival was 12 months from EV start. Discussion: Cavitation likely reflects treatment-related necrosis once infection and EV-related pneumonitis are excluded. Diameter-based criteria can misjudge response when solid nodules cavitate; short-interval re-imaging is advisable. Pulmonary response may not ensure systemic control. Conclusion: Recognizing EV-associated cavitation as a response pattern may prevent premature discontinuation of effective therapy and unnecessary antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.